- FDA D.I.S.C.O. Burst Edition: FDA approval of ABECMA (idecabtagene vicleucel) the first FDA approved cell-based gene therapy for the treatment of adult patients with relapsed or refractory multiple myeloma
- Los resultados iniciales de un ensayo de seguridad revela un mayor riesgo de padecer problemas graves relacionados con el corazón y cáncer con los medicamentos para la artritis y la colitis ulcerosa Xeljanz y Xeljanz de liberación prolongada (tofacitinib)
- Prescription Drug User Fee Amendments
- Patent Certifications and Suitability Petitions
- FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) for patients with metastatic or locally advanced esophageal or gastroesophageal carcinoma
- Medicamentos
- FDA D.I.S.C.O. Burst Edition: Libtayo (cemiplimab-rwlc) for first-line treatment of patients with advanced NSCLC (locally advanced who are not candidates for surgical resection or definitive chemoradiation or metastatic) whose tumors have high PD-L1 expression with no eGFR, anaplastic lymphoma kinase or receptor tyrosine kinase aberrations
- FDA D.I.S.C.O. Burst: Approval of Pepaxto (melphalan flufenamide) in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received at least four lines of prior therapy
- FDA D.I.S.C.O. Burst Edition: Lorbrena (lorlatinib) for patients with metastatic non-small cell lung cancer whose tumors are anaplastic lymphoma kinase-positive, detected by an FDA-approved test
- FDA D.I.S.C.O. Burst Edition: FDA approval of Fotivda (tivozanib) for adult patients with relapsed or refractory advanced renal cell carcinoma following two or more prior systemic therapies
- Remarks by Dr. Janet Woodcock to the 2021 Rx Drug Abuse and Heroin Summit - 04/08/2021
- MedWatch Forms for FDA Safety Reporting
- CPG Sec. 160.300 Requests for Records Under Section 703
- Drug Trials Snapshots
- FDA updates on hand sanitizers consumers should not use
- User Fee Lists
- Consumer Updates
- CPG Sec. 160.600 Payment of Expert Witnesses
- CPG Sec. 160.200 FDA Use of Income Tax Information from IRS in Compliance Activity
- CPG Sec. 150.100 Requests for Portions of Intermediate or End Products Resulting from FDA Sample Analysis
- CPG Sec. 140.100 Seizure of Books that Constitute Misleading Labeling
- MedWatch: The FDA Safety Information and Adverse Event Reporting Program
- CPG Sec. 160.400 *Section 305 Meeting* Before Report of Criminal Violation
- CPG Sec. 160.500 Answering Inquiries on Status of Criminal Referrals
- CPG Sec. 130.400 Use of Microfiche and/or Microfilm for Method of Records Retention
- CPG Sec. 160.750 Drug and Device Products (Including Biologics and Animal Drugs) Found in Violation of GMPRs - Reconditioning
- CPG Sec. 130.300 FDA Access to Results of Quality Assurance Program Audits and Inspections
- CPG Sec. 400.210, Radiofrequency Identification Feasibility Studies and Pilot Programs for Drugs
- NS NY Distributor Inc Issues Voluntary Nationwide Recall of Premium OrgaZen 7000 and Ginseng Power 5000 Due to Presence of Undeclared Sildenafil and/or Tadalafil
- CDER Scientific Review Documents Supporting Emergency Use Authorizations for Drug and Biological Therapeutic Products | COVID-19